FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set PDUFA target action date ...

FDA granted priority review to Company's BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis and set ...

The FDA has accepted for Priority Review the BLA for PRGN-2012 for the treatment of adults with recurrent respiratory papillomatosis.

for the treatment of adults with recurrent respiratory papillomatosis (RRP). RRP is a rare neoplastic disease caused by an infection with human papillomavirus (HPV) 6 or 11. It is characterized by ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP) ...

PRGN-2012 is designed to elicit immune responses directed against cells infected with human papillomavirus, or HPV, 6 or HPV 11. PRGN-2012 received Breakthrough Therapy Designation, Orphan Drug ...

Precigen has won U.S. Food and Drug Administration priority review for its application seeking approval of its proposed PRGN-2012 gene therapy for adults with recurrent respiratory papillomatosis ...

Infection with HPV 6 or HPV 11 causes RRP, a lifelong neoplastic disease of the upper and lower respiratory tracts that can be fatal. According to Precigen, some 27,000 U.S. adults have RRP based ...

a rare and debilitating disease caused by HPV 6 and HPV 11 infections. If approved, PRGN-2012 will be the first FDA-approved therapy for RRP, which currently has no cure, and patients rely on ...

Significant progress toward submitting a biologics license application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis ... treatment for HPV 16/18 positive ...

Inovio’s lead candidate, INO-3107, targets recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) infections. The company is on track to submit a ...